PUMA BIOTECHNOLOGY, INC. Deferred Tax Assets, Other
PUMA BIOTECHNOLOGY, INC. (PBYI) had Deferred Tax Assets, Other of $5.72 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOther · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Other $5.72M.
- 2024-12-31: Deferred Tax Assets, Other $4.75M.
- 2023-12-31: Deferred Tax Assets, Other $4.23M.
- 2022-12-31: Deferred Tax Assets, Other $3.56M.
| Period end | Deferred Tax Assets, Other |
|---|---|
| 2025-12-31 | $5.72M 10-K · filed 2026-02-26 |
| 2024-12-31 | $4.75M 10-K · filed 2026-02-26 |
| 2023-12-31 | $4.23M 10-K · filed 2026-02-26 |
| 2022-12-31 | $3.56M 10-K · filed 2025-02-27 |
| 2021-12-31 | $1.31M 10-K · filed 2024-02-29 |
| 2020-12-31 | $804.00K 10-K · filed 2023-03-02 |
| 2019-12-31 | $13.00K 10-K · filed 2022-03-03 |
| 2017-12-31 | $806.00K 10-K · filed 2019-03-01 |
| 2016-12-31 | $997.00K 10-K · filed 2018-03-09 |
| 2015-12-31 | $62.00K 10-K · filed 2017-03-01 |
| 2014-12-31 | $84.00K 10-K · filed 2016-02-29 |
| 2013-12-31 | $85.00K 10-K · filed 2015-03-02 |
| 2012-12-31 | $75.00K 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |